- Home
- PUMP vs COGT Comparison
PUMP vs COGT Comparison
Compare PUMP & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUMP
- COGT
- Stock Information
- Founded
- PUMP 2007
- COGT 2014
- Country
- PUMP United States
- COGT United States
- Employees
- PUMP N/A
- COGT N/A
- Industry
- PUMP Oilfield Services/Equipment
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- PUMP Energy
- COGT Health Care
- Exchange
- PUMP Nasdaq
- COGT Nasdaq
- Market Cap
- PUMP 938.7M
- COGT 895.8M
- IPO Year
- PUMP 2017
- COGT 2018
- Fundamental
- Price
- PUMP $10.88
- COGT $8.03
- Analyst Decision
- PUMP Buy
- COGT Buy
- Analyst Count
- PUMP 7
- COGT 6
- Target Price
- PUMP $11.17
- COGT $14.17
- AVG Volume (30 Days)
- PUMP 1.9M
- COGT 1.5M
- Earning Date
- PUMP 02-19-2025
- COGT 02-24-2025
- Dividend Yield
- PUMP N/A
- COGT N/A
- EPS Growth
- PUMP N/A
- COGT N/A
- EPS
- PUMP N/A
- COGT N/A
- Revenue
- PUMP $1,471,508,000.00
- COGT N/A
- Revenue This Year
- PUMP N/A
- COGT N/A
- Revenue Next Year
- PUMP N/A
- COGT N/A
- P/E Ratio
- PUMP N/A
- COGT N/A
- Revenue Growth
- PUMP N/A
- COGT N/A
- 52 Week Low
- PUMP $6.54
- COGT $4.28
- 52 Week High
- PUMP $11.16
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- PUMP 76.42
- COGT 46.50
- Support Level
- PUMP $10.51
- COGT $6.60
- Resistance Level
- PUMP $10.55
- COGT $8.72
- Average True Range (ATR)
- PUMP 0.40
- COGT 0.51
- MACD
- PUMP 0.10
- COGT 0.09
- Stochastic Oscillator
- PUMP 87.11
- COGT 67.45
About PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and coiled tubing.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.